Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Melanoma
Research results from Vrije University, Medical Department update understanding of melanoma
July 7th, 2009
"A critical factor determining the effectiveness of currently used dendritic cell (DC)-based vaccines is the DC activation or maturation status. We have recently shown that the T-cell stimulatory capacity of DCs pulsed with tumor-antigen-derived peptides can be considerably increased by activating the DCs through electroporation with mRNA encoding CD40 ligand, CD70, and a constitutively active Toll-like receptor 4 (TriMix DCs)," scientists in Brussels, Belgium report. "Here, we investigate whether TriMix DCs can be coelectroporated with whole tumor-antigen-encoding mRNA. The T-cell stimulatory capacity of TriMix DCs pulsed with the immunodominant MelanA-A2 peptide and...
Source: Cancer Weekly (2009-07-07)
|
